NCT01266642View on ClinicalTrials.gov

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

February 8, 2011

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2025

Conditions
Ductal Breast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v6Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7
Interventions
RADIATION

External Beam Radiation Therapy

Undergo HF-WBI

RADIATION

External Beam Radiation Therapy

Undergo CF-WBI

RADIATION

Hypofractionated Radiation Therapy

Undergo HF-WBI

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Whole Breast Irradiation

Undergo HF-WBI

RADIATION

Whole Breast Irradiation

Undergo CF-WBI

Trial Locations (7)

32806

UF Cancer Center at Orlando Health, Orlando

77030

M D Anderson Cancer Center, Houston

77079

MD Anderson West Houston, Houston

77384

MD Anderson in The Woodlands, Conroe

77478

MD Anderson in Sugar Land, Sugar Land

77573

MD Anderson League City, League City

85234

Banner MD Anderson Cancer Center, Gilbert

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER